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Introduction
============

Remarkably, neurons have the ability to undergo long-lasting changes in the strength and pattern of their synaptic connectivity in response to environmental stimuli. Long-term modification of synapses is thought to mediate many aspects of brain functions, particularly learning and memory ([@bib22]). In general, long-term synaptic plasticity has two distinct features. First, long-lasting changes in the structure of synapses accompany alterations in synaptic efficacy that include both the modification of existing synapses and the formation of new synapses. Second, long-term synaptic plasticity requires changes in gene expression and new protein synthesis ([@bib15]; [@bib74]). The transcription factor cAMP response element (CRE)--binding protein (CREB) is thought to play a key role in the synthesis of new proteins required for long-term synaptic plasticity.

CREB, which is a member of basic leucine zipper (bZIP) family of dimeric transcription factors, controls the expression of many plasticity-related genes through binding to the CRE. Numerous studies have established that CREB plays a critical role in long-term synaptic plasticity and memory in a variety of model systems, such as flies, mollusks, and rodents ([@bib63]; [@bib30]; [@bib38]; [@bib70]; [@bib17]). Is CREB involved in both structural and functional modifications of synapses? Inhibition of CREB activity in *Aplysia* blocks both long-term facilitation of synaptic efficacy and synaptic growth ([@bib9]). In *Drosophila melanogaster*, however, CREB controls only functional, and not structural, synaptic plasticity ([@bib14]). Gene knockout experiments in mice have yielded variable results regarding hippocampal synaptic plasticity. Some investigators have reported that disruption of CREB function impairs some forms of long-term potentiation (LTP; [@bib11]; [@bib54]), whereas others find no considerable LTP deficits ([@bib21]; [@bib57]; [@bib6]; [@bib56]). There is some evidence that CREB is also involved in structural changes at hippocampal synapses ([@bib48]).

Recently, neurotrophins have emerged as major factors that regulate synaptic structure and function ([@bib55]; [@bib39]; [@bib41]). These factors are widely expressed in the brain, and can elicit both acute and long-term modifications of synapses ([@bib40]). In general, neurotrophins bind to their cognate Trk receptor tyrosine kinases and initiate their synaptic functions through the following three signaling pathways: MAPK, phosphatidylinositol 3-kinase, and PLC-γ ([@bib32]; [@bib26]). An important task is to determine the signaling mechanisms for specific neurotrophins in specific aspects of synaptic modulation. Several lines of evidence suggest that long-term synaptic modulation by neurotrophins also involves synaptic growth and requires new protein synthesis ([@bib40]). Long-term treatment of hippocampal slices with brain-derived neurotrophic factor increases the number of synapse, spine density, and synaptic proteins in rodent CA1 pyramidal neurons ([@bib64]; [@bib66]). In cultured *Xenopus laevis* neuromuscular synapses, long-term exposure to neurotrophin-3 (NT-3) induces a series of profound structural changes, specifically, an increase in the number and size of synaptic varicosities ([@bib69]). In a recent study, we demonstrated that the long-term structural changes at the neuromuscular synapses induced by NT-3 require protein synthesis in the presynaptic neurons ([@bib28]).

Does long-term synaptic modulation by neurotrophins require the transcription factor CREB? What are the relationships between structural and functional changes at synapses induced by neurotrophins? In this study, we used the *X. laevis* neuromuscular synapses as a model system to study the signaling mechanisms underlying the structural and functional plasticity induced by NT-3. We demonstrated that although NT-3--induced enhancement in the efficacy at a single synapse requires CREB activation in presynaptic neurons, the long-term increase in the number of synaptic sites elicited by NT-3 is CREB-independent. Instead, the morphological changes in the presynaptic terminals require activation of the MAPK pathway. Thus, the structural and functional synaptic modifications by NT-3 are mediated by separate mechanisms. Using various imaging tools, we have also identified signaling events upstream of CREB and MAPK. Together, these data argue that a concomitant activation of CaMKIV--CREB--mediated transcription and sustained Rap1--MAPK signaling may be necessary for the long-term functional and structural changes necessary for neurotrophin-dependent synaptic modulation.

Results
=======

Requirement of CREB activation in NT-3--induced long-term synaptic potentiation
-------------------------------------------------------------------------------

CREB activation is critical for several forms of sustained synaptic plasticity ([@bib29], [@bib30]; [@bib63]). It is unclear, however, whether CREB mediates the long-term synaptic modulation by neurotrophins. To measure CREB activation, we used an antibody that detects the phosphorylation at serine 133 of CREB. *X. laevis* spinal neurons exhibited rapid activation of CREB (\<30 min) after NT-3 treatment (5 ng/ml), as indicated by dark nuclear staining ([Fig. 1 A](#fig1){ref-type="fig"}). To better quantify CREB activation, we used immunofluorescence, and measured the peak fluorescence intensity in the nuclear region ([Fig. 1, B and C](#fig1){ref-type="fig"}, and Fig. S1 A, available at <http://www.jcb.org/cgi/content/full/jcb.200603061/DC1>). Compared with untreated neurons, NT-3 treatment increased the level of fluorescence signals in the nucleus of spinal neurons by threefold ([Fig. 1 C](#fig1){ref-type="fig"}).

![**NT-3 activates CREB via CaMKs.** *X. laevis* nerve-muscle cultures were treated with or without inhibitors for 1 h, followed by application of NT-3. The cultures were fixed 30 min later and processed for immunocytochemistry using anti-pCREB antibody. (A) pCREB staining images of cultures treated with or without 5 ng/ml NT-3. The yellow arrow indicates dark nuclear staining by pCREB. N, neuron; M, muscle cell. Bar, 20 μm. (B) Fluorescence intensity profiles of pCREB staining in the cell body of spinal neurons. Higher magnification of neuronal cell body is shown in the top right corner. The intensity of pCREB fluorescence was monitored along the axis drawn on the cell body of spinal neurons. Bar, 10 μm. *n* = 8 for untreated neurons; *n* = 10 for NT-3--treated neurons. (C) Quantification of peak intensity of pCREB fluorescence under various conditions. The number associated with each column represents the number of cells analyzed. \*, significantly higher than the respective NT-3(--) group, by ANOVA, followed by post hoc tests; P \< 0.01. (D) Time course of CREB activation upon NT-3 treatment with or without 10 μM MAPK inhibitor (PD098059) or 1 μM CaMK inhibitor (KN93). The peak intensities of pCREB fluorescence at various time points were monitored after NT-3 treatment. Data are presented as the mean ± the SEM.](jcb1751029f01){#fig1}

CREB can be phosphorylated on serine 133 by multiple kinases, including protein kinase A (PKA), calcium/calmodulin-dependent kinases (CaMKs), and MAPK. To identify the signaling pathways mediating the CREB activation, we examined phospho-CREB (pCREB) fluorescence in cultured spinal neurons in the presence of inhibitors specific for these pathways. Pretreatment of spinal neurons with the MAPK kinase (MEK) inhibitor PD098059 (10 μM; [@bib2]) or PKA inhibitor Rp-cAMP (5 μM; [@bib45]) for 1 h could not attenuate the increase in pCREB fluorescence after NT-3 application ([Fig. 1 C](#fig1){ref-type="fig"}). In contrast, pretreatment with the CaM kinase inhibitor KN93 (1 μM; [@bib13]) completely prevented the increase in pCREB fluorescence induced by NT-3 ([Fig. 1 C](#fig1){ref-type="fig"}). These data suggest that CREB activation, at least within 1 h after NT-3 application, is mediated through the CaMKs.

It has been reported that in hippocampal neurons, CaMKIV is responsible for early activation of CREB, whereas the late, sustained phosphorylation of CREB depends on MAPK activity ([@bib72]). To examine whether CaMK or MAPK mediates the sustained CREB phosphorylation in developing spinal neurons, we monitored the time course of CREB activation in the presence or absence of specific inhibitors. NT-3 treatment significantly increased CREB phosphorylation as early as 30 min, and maximum activation of CREB was observed 1 h after NT-3 treatment (P \< 0.05; [Fig. 1 D](#fig1){ref-type="fig"}). This increase was maintained at 93% level until 24 h after NT-3 treatment, indicating that NT-3 induced a sustained phosphorylation of CREB. The sustained activation of CREB was abolished by KN93, but not PD098059 ([Fig. 1 D](#fig1){ref-type="fig"}). Thus, in developing spinal neurons, NT-3--induced CREB phosphorylation is mediated by CaMKs, not MAPK.

NT-3 is known to induce both acute and long-term changes in synaptic efficacy at the neuromuscular synapses ([@bib69]; [@bib36]; [@bib37]; [@bib41]). To determine whether CREB activation is necessary for either the acute or the long-term effects of NT-3, we introduced dominant-negative CREB (DnCREB) mutants into spinal neurons by embryo injection. Two different DnCREB mutants were used; the K-CREB, a mutant that contains mutations in the DNA-binding domain of CREB; and the A-CREB, a mutant that contains basic-to-acidic residue mutations within the CREB bZIP domain ([@bib68]; [@bib1]). These variants of CREB proteins act as dominant repressors for gene transcription by forming an inactive dimer with endogenous CREB and blocking its ability to bind cAMP response element (CRE). Therefore, expression of these DnCREB mutants cannot change the phosphorylation status of Ser133 in the endogenous CREB, but can still inhibit CREB-mediated gene transcription. The mRNAs of DnCREB mutants were coinjected with GFP mRNAs into one blastomere of *X. laevis* embryos at the two-cell stage. Nerve-muscle cocultures were prepared from the injected embryos after 24 h. Expression of K-CREB in spinal neurons had no effect on the basal synaptic transmission. The frequency of spontaneous synaptic currents (SSCs) recorded from K-CREB--positive (N+) and K-CREB--negative (N−) neurons were 4.7 ± 0.5 events/min (*n* = 11) and 4.3 ± 0.6 events/min (*n* = 7), respectively. Moreover, identical to that observed in control synapses (N--), acute application of NT-3 induced an increase in frequency, but not amplitude, of SSCs ([Fig. 2 A](#fig2){ref-type="fig"}). Collectively, inhibition of CREB activation does not affect the acute modulation of transmission by NT-3.

![**Presynaptic expression of DnCREB prevents the long-term effect of NT-3 on synaptic transmission.** In this and all other figures, presynaptic expression of a specific gene was achieved by embryo mRNA injection. The acute effect of NT-3 was studied by directly applying 25 ng/ml NT-3 to 1-d-old cultures, and the long-term effect of NT-3 was studied by treating cultures with 5 ng/ml NT-3 for 48 h. The frequency of SSCs was used to monitor changes in synaptic efficacy. (A) Inhibition of CREB activation did not prevent acute potentiation of synaptic transmission by NT-3. (top) A sample recording showing that acute application of NT-3 still elicits a rapid increase in the frequency of SSCs recorded from a synapse in which K-CREB is expressed presynaptically (N+). (bottom) Summary of effect of acute application of NT-3 on control synapses (N--) without K-CREB, and synapses with presynaptic (N+) expression of K-CREB. Each data point represents normalized SSCs frequency (averaged from 10 min of recording) from a single synapse before and after NT-3 application. (B and D) Presynaptic, but not postsynaptic, expression of K-CREB prevents NT-3--induced long-term synaptic potentiation on SSC frequency (B) and ESC amplitude (D). M+, K-CREB expressed postsynaptically. (C) Presynaptic expression (N+) of A-CREB prevents NT-3--induced long-term synaptic potentiation. The number associated with each column represents the number of cells analyzed. Data are presented as the mean ± the SEM.](jcb1751029f02){#fig2}

In contrast, expression of K-CREB in presynaptic neurons completely blocked the enhancement of synaptic efficacy induced by long-term exposure to NT-3. In a culture treated with NT-3 for 48 h, the mean SSC frequency of the synapses made by K-CREB--expressing neurons was reduced to the level of NT-3--untreated neurons ([Fig. 2 B](#fig2){ref-type="fig"}). However, expression of K-CREB in the postsynaptic muscle cells had no effect on NT-3--induced long-term synaptic potentiation ([Fig. 2 B](#fig2){ref-type="fig"}), suggesting that CREB activation is only required in presynaptic neurons. Moreover, expression of K-CREB either pre- or postsynaptically had no effect on SSC amplitude, whether the synapses were treated with NT-3 or not (Fig. S2 A, available at <http://www.jcb.org/cgi/content/full/jcb.200603061/DC1>). Almost identical results were obtained from synapses expressing A-CREB presynaptically ([Fig. 2 C](#fig2){ref-type="fig"}). In addition to potentiating spontaneous synaptic activity, long-term treatment with NT-3 enhances functional synaptic transmission, as reflected by an increase in the amplitude of evoked synaptic currents (ESCs), which are elicited by stimulating presynaptic somata of spinal neurons ([@bib28]). Expression of K-CREB in presynaptic spinal neurons completely blocked the increase in ESC amplitude induced by NT-3 ([Fig. 2 D](#fig2){ref-type="fig"}). Collectively, these results suggest that presynaptic activation of CREB is required for NT-3-- induced long-term, but not acute, synaptic transmission at the neuromuscular synapses.

Long-term physiological effect of NT-3 mediated by the CaMKIV--CREB pathway
---------------------------------------------------------------------------

Given that CaMK signaling was required for NT-3--induced CREB activation ([Fig. 1, C and D](#fig1){ref-type="fig"}), we next asked whether the CaMK pathway also mediates the long-term effects of NT-3. Treatment with NT-3 for 48 h increased the frequency of SSCs by ∼2.5-fold over untreated control cells ([Fig. 3 A](#fig3){ref-type="fig"}). In contrast, in cultures pretreated with 1 μM KN93, NT-3 elicited no increase in SSC frequency, indicating that NT-3--induced synaptic potentiation requires activation of the CaMK signaling pathway. Inhibition of either MAPK ([@bib28]) or PKA (Fig. S2 D) did not exhibit statistically significant change in NT-3--induced long-term physiological effects. Therefore, these data suggest that the NT-3--induced long-term physiological effect is primarily mediated through a CaMK-dependent mechanism.

![**NT-3--induced CREB activation and long-term physiological change are mediated by CaMKIV.** (A) Inhibition of CaMKs prevents NT-3--induced long-term synaptic potentiation. Cultures were treated with or without 1 μM KN93, which is a specific inhibitor for CaMKs. (B and C) Expression of Dn-CaMKIV abolishes CREB activation induced by NT-3. (B) Bright-field (top left), pCREB (top right, red), Dn-CaMKIV (bottom left, green), and merged fluorescence images (bottom right) of three spinal neurons, two of which express Dn-CaMKIV, as indicated by coexpression of GFP. After application of NT-3, the Dn-CaMKIV--negative neuron exhibit marked CREB phosphorylation (red). In contrast, the Dn-CaMKIV--expressing neuron (green) shows no CREB phosphorylation. Note that the neuron in the middle expresses a lower level of Dn-CaMKIV and shows a reduced CREB phosphorylation. Bar, 10 μm. White dashed lines indicate the outline of neuronal cell bodies. (C) Quantitative analysis of pCREB levels in Dn-CaMK (+) and (--) neurons before and after NT-3 application. (D and E) Inhibition of NT-3--induced long-term synaptic potentiation by presynaptic expression of Dn-CaMKIV. Dn-CaMKIV was expressed in spinal neurons. SSC frequency and ESC amplitude were measured in synapses treated with or without NT-3 for 2 d. (D) Effects on SSC frequency. (E) Effects on ESC amplitude. The number associated with each column represents the number of cells analyzed. Data are presented as the mean ± the SEM.](jcb1751029f03){#fig3}

KN93 is a general inhibitor of CaMK family members, which include CaMKI, CaMKII, and CaMKIV, but CaMKI and CaMKII are enriched in neuronal processes and synapses, whereas CaMKIV is relatively enriched in the nucleus ([@bib16]; [@bib20]; [@bib53]). The nuclear localization of CaMKIV suggests its ability to link extracellular signals to CREB activation in the nucleus. Therefore, we tested whether CaMKIV mediates both CREB activation and the long-term synaptic effects elicited by NT-3 by using Dn-CaMKIV. This mutant of CaMKIV bears a T196A mutation, which disrupts CaMKIV from binding to CaMKIV kinases ([@bib65]). Expression of the Dn-CaMKIV mutant was reflected by GFP fluorescence in cultured spinal neurons ([Fig. 3 B](#fig3){ref-type="fig"}). NT-3 treatment for 30 min caused an approximately fourfold increase in pCREB immunoreactivity in control spinal neurons, but not in neurons expressing Dn-CaMKIV ([Fig. 3 C](#fig3){ref-type="fig"}). These findings are consistent with a recent study showing that expression of Dn-CaMKIV could attenuate CREB activation and CREB-mediated transcription in hippocampal neurons ([@bib31]).

Cells expressing the Dn-CaMKIV mutant did not display any defect in growth or morphology (unpublished data). To determine whether CaMKIV activation is required for long-term effects of NT-3 on synaptic transmission, we measured SSC frequency in spinal neurons expressing Dn-CaMKIV mutant. Expression of Dn-CaMKIV in spinal neurons completely blocked the enhancement of synaptic efficacy induced by long-term exposure to NT-3 ([Fig. 3, D and E](#fig3){ref-type="fig"}). In cultures treated with NT-3 for 48 h, the frequency of SSCs in the synapses made by Dn-CaMKIV--expressing neurons was significantly lower than that in synapses made by nonexpressing control neurons in the same dishes ([Fig. 3 D](#fig3){ref-type="fig"}). Dn-CaMKIV had no effect on SSC amplitude, suggesting a pure presynaptic effect (Fig. S2 B). Expression of Dn-CaMKIV in presynaptic neurons also completely prevented the potentiating effect of NT-3 on ESC amplitude ([Fig. 3 E](#fig3){ref-type="fig"}). Inhibition of CaMKII with a specific peptide inhibitor blocked the acute potentiation of synaptic transmission by NT-3 ([@bib24]). In neurons expressing the Dn-CaMKIV, however, acute application of NT-3 could still elicit a marked increase in SSC frequency (Fig. S3, available at <http://www.jcb.org/cgi/content/full/jcb.200603061/DC1>). Thus, the acute effect of NT-3 on synaptic transmission is mediated by CaMKII, whereas the long-term effect is mediated by CaMKIV. These results suggest that the long-term effect of NT-3 on synaptic transmission is mediated by the CaMKIV--CREB pathway.

NT-3--induced translocation of GFP-CaM into nucleus
---------------------------------------------------

CaMKIV activation requires the translocation of Ca^2+^-calmodulin (CaM) into the nucleus, and such nuclear translocation of CaM appears to be important for the activation of CaMKIV--CREB pathway ([@bib16]). To test whether NT-3 is capable of inducing nuclear localization of CaM, we expressed GFP-CaM fusion protein in spinal neurons ([@bib35]). Expression of GFP-CaM did not affect the normal growth or morphology of neurons ([Fig. 4 A](#fig4){ref-type="fig"}, left). Western blot showed the expression of GFP-CaM in *X. laevis* neural tubes 2 d after embryonic DNA injection. In embryos injected with GFP-CaM cDNA, a prominent band of 47 kD was detected using an anticalmodulin antibody. This band was also stained positively with antibody against GFP, confirming the expression of GFP-CaM fusion protein ([Fig. 4 A](#fig4){ref-type="fig"}, right).

![**NT-3 induces the translocation of CaM into the nucleus of spinal neurons.** (A) Expression of the GFP-CaM fusion gene in *X. laevis* spinal neurons. Hoffman and fluorescent images (left and middle) show a spinal neuron expressing GFP-CaM. Bars (A and B), 20 μm. (right) Western blots showing the expression of the GFP-CaM in 1-d-old neural tubes injected with or without (Control) CaM mRNA. (B) Redistribution of CaM in spinal neurons induced by NT-3. (top) Color-coded images of a CaM-GFP--expressing spinal neuron before and after NT-3 application. Two ROIs for monitoring fluorescence changes (free-hand ROI traces over nucleus and axon) are shown. At the peak of the response (30 min after NT-3 application), the nuclear area is bright red, indicating a substantial accumulation of GFP-CaM in the region. (bottom) Application of NT-3 evoked a slow, but sustained, increase (from 10 min after NT-3 application) in the fluorescence signal from the nucleus region (blue trace), accompanied by a corresponding decrease in the fluorescence intensity from the axonal area (pink trace). Averaged florescence signals at 30 min are shown on the right. The number associated with each column represents the number of cells analyzed. Data are presented as the mean ± the SEM.](jcb1751029f04){#fig4}

We next studied the NT-3--induced movement of GFP-CaM in spinal neurons. GFP-CaM fluorescence was monitored in the nucleus and axonal periphery of neurons. Before application of NT-3, culture medium was replaced with Ringer\'s solution for 2 h to reduce the background CaM movement caused by unspecified factors accumulated in the medium. Fluorescence intensity changes of selected areas in the nucleus and axons of a neuron (indicated by dotted lines in [Fig. 4 B](#fig4){ref-type="fig"}, top) upon NT-3 application were monitored by using time-lapse microscopy. Application of NT-3 evoked a rise in the fluorescence in the nucleus, paralleling a decrease in the fluorescence intensity in the axons ([Fig. 4 B](#fig4){ref-type="fig"}, top). The increase in nuclear CaM fluorescence was relatively fast; within 20 min, the nuclear fluorescence reached a plateau ([Fig. 4 B](#fig4){ref-type="fig"}, bottom left). In all experiments, the total averaged cellular fluorescence (corrected for photobleaching effects) remained unchanged, indicating that observed fluorescence intensity changes are caused by redistribution of GFP-CaM. Application of NT-3 for 30 min increased the intensity of nuclear fluorescence by 29%, but decreased that of the axonal fluorescence by 35%. These results indicate that application of NT-3 evoked active translocation of CaM from nonnuclear regions into nuclear region in neurons.

Long-term morphological effects of NT-3 mediated by MAPK pathway
----------------------------------------------------------------

In addition to physiological changes, long-term treatment with NT-3 induces the morphological development of presynaptic terminals ([@bib36]; [@bib69]). Using FM dye to label endocytosed synaptic vesicles, our previous study showed that chronic, but not acute, treatment with NT-3 promotes the formation of "synaptic varicosities," which are enlargements along the axons that reflect clusters of synaptic vesicles and other presynaptic elements ([@bib28]). There are two potential problems associated with this approach. First, FM dye also labels postsynaptic membrane structures and organelles. To avoid this problem, we visualized the synaptic varicosity by expressing a fusion protein in which GFP is fused with the C terminus of synaptophysin (SYP-GFP), a major integral membrane protein of synaptic vesicles ([@bib3]; [@bib60]). SYP-GFP was coinjected with rhodamine-dextran in *X. laevis* embryos so that we could simultaneously label axonal morphology and synaptic varicosity ([Fig. 5, A--C](#fig5){ref-type="fig"}). Furthermore, to ensure that SYP-GFP labels functional synaptic vesicles, neurons transiently transfected with SYP-GFP were loaded with FM 4--64 dye. We found that that SYP-GFP fluorescence overlapped completely with FM dye--labeled structures at the presynaptic terminals ([Fig. 6](#fig6){ref-type="fig"}). The second problem is that labeling presynaptic vesicles alone may not faithfully reveal specific changes in the presynaptic terminals at the synapses. Therefore, we labeled postsynaptic acetylcholine receptors (AChRs) with a low concentration of Cy5-labeled α-bungarotoxin ([Fig. 5 D](#fig5){ref-type="fig"}, Cy5-α-BTX). The "synaptic site" was revealed by the juxtaposition of presynaptic SYP-GFP (green) and postsynaptic AChR ([Fig. 5, E and F](#fig5){ref-type="fig"}, red).

![**Synaptic sites are revealed by double labeling with SYP-GFP and Cy5-α-BTX.** (A) Phase-contrast image of nerve-muscle coculture. M, myocytes. (B) Labeling of axons of a spinal neuron by rhodamine dextran. (C) Labeling of synaptic varicosities by SYP-GFP. Note the discrete SYP puncta located in presynaptic terminals innervating the myocytes. (D) Labeling of postsynaptic AChRs with Cy5-α-BTX. (E) Merge of images in C and D. (F) Enlargement of the areas boxed in E. Note that SYP-GFP (green) and Cy5-α-BTX (red) puncta are juxtaposed against each other at the synapses. Bar, 10 μm.](jcb1751029f05){#fig5}

![**SYP-GFP--labeled synaptic varicosities are colocalized with FM dye--labeled puncta.** Neurons transiently transfected with SYP-GFP were loaded with FM 4--64 dye by rapid depolarization (2 min) with high K^+^ and neurons, followed by extensive washing.(A) Phase-contrast images of nerve-muscle coculture. (B) Labeling of synaptic varicosities by SYP-GFP. (C) Labeling of synaptic varicosities by FM 4--64. Yellow arrows indicate synaptic varicosities in which SYP-GFP and FM dye are colocalized. (D) Merge of images in B and C. More than 20 neurons were examined, and consistent colocalization of SYP-GFP and FM dye were observed in puncta located in the synaptic regions. Bar, 10 μm.](jcb1751029f06){#fig6}

Using the double-labeling technique, we showed that chronic treatment (48 h) of NT-3 significantly increased the number of synaptic sites ([Fig. 7 A](#fig7){ref-type="fig"}). To test the role of CREB in NT-3--induced long-term morphological changes, we inhibited CREB activation by expressing K-CREB in spinal neurons and quantified the changes in synaptic sites. Treatment with NT-3 induced a twofold increase in the number of synaptic sites per myocyte. Surprisingly, although expression of K-CREB blocked the physiological changes of synapses triggered by NT-3, expression of K-CREB in spinal neurons could not inhibit a NT-3--induced increase in synaptic sites ([Fig. 7 B](#fig7){ref-type="fig"}). These results suggest that CREB activation is only required for functional, but not structural, changes of synapses induced by NT-3. Furthermore, these results raise the possibility of parallel signaling pathways mediating NT-3--induced functional and morphological changes.

![**Long-term NT-3 treatment increases the number of synaptic sites via MAPK, but not CREB.** (A) Effect of NT-3 on the number of synaptic sites. Synaptic sites (yellow spots, indicated by yellow arrows) are revealed by synaptic boutons (labeled by SYP-GFP, green) directly juxtaposed to postsynaptic AChR (labeled by Cy5-α-BTX; red). (B) Failure of K-CREB to block a NT-3--induced increase on synaptic sites. (C) Selective blockade of NT-3--induced long-term changes in synaptic sites by inhibition of MAPK pathway. The MEK inhibitor U0126, but not the PKA inhibitor Rp-cAMP or the CaMK inhibitor KN93, prevented the increase in synaptic sites induced by NT-3. The number associated with each column represents the number of cells analyzed. Data are presented as the mean ± the SEM.](jcb1751029f07){#fig7}

What are the signaling pathways that mediate the increase in the number of synaptic sites induced by long-term exposure to NT-3? NT-3 is known to activate MAPK in *X. laevis* spinal neurons ([@bib73]). Given that neurotrophins have been shown to promote neurite outgrowth via MAPK pathway in cortical neurons and PC12 cells ([@bib42]), we sought to test whether MAPK activation is required for NT-3--induced increase in synaptic varicosity. Treatment with the MEK inhibitor U0126, which is known to block NT-3--induced MAPK activation ([@bib73]), completely blocked changes in synaptic sites elicited by NT-3 ([Fig. 7 C](#fig7){ref-type="fig"}). However, neither the PKA inhibitor Rp-cAMP nor the CaMK inhibitor KN93 could block the NT-3 effect ([Fig. 7 C](#fig7){ref-type="fig"}). These results, together with the finding that MAPK is not involved in the long-term changes in synaptic efficacy induced by NT-3 ([@bib28]), reveal a complementary role of MAPK and CREB; MAPK mediates the morphological, whereas CREB mediates physiological, changes induced by NT-3.

Requirement of Rap1, but not Ras, for long-term morphological effects of NT-3
-----------------------------------------------------------------------------

If CaMKIV is the upstream activator for CREB that mediates the functional changes of synapses upon NT-3 treatment, what is the upstream activator for MAPK that mediates the structural change of synapse induced by NT-3? In PC12 cells, Ras and Rap1, two related small GTP-binding proteins of the Ras subfamily, have been shown to mediate transient and sustained activation of MAPK, respectively ([@bib76]). To monitor the kinetics of Ras and Rap1 activation by NT-3 in living spinal neuron, we used fluorescent resonance energy transfer (FRET) techniques using Raichu-Ras and -Rap1 constructs ([@bib47]). Raichu-Ras contains a pair of mutant fluorescence proteins (YFP and CFP) in its C terminus. Thus, activation of Ras caused by intramolecular binding of the Ras domain to the RafRBD domain brings CFP close to YFP, leading to FRET from CFP to YFP ([Fig. 8 A](#fig8){ref-type="fig"}). Raichu-Rap1 works very similarly, except Ras is replaced with Rap1. We found that the activation of Ras differed from that of Rap1 in two ways. First, Ras activation, as reflected by the color change, was faster and more transient than Rap1 activation ([Fig. 8](#fig8){ref-type="fig"}, A \[top\] and B). Ras activation reached its maximum in \<10 min and was diminished in 90 min ([Fig. 8 B](#fig8){ref-type="fig"}). This may reflect the localization of Ras at the plasma membrane, where NT-3/TrkC signals were rapidly transduced ([Fig. 8 B](#fig8){ref-type="fig"}). In contrast, Rap1 activation was much slower and more sustained. Second, Ras activation was observed not only in the cell body, but also in the axonal processes. In contrast, Rap1 activation was concentrated primarily at the neuronal cell body and never extended to the axons ([Fig. 8](#fig8){ref-type="fig"}, A \[bottom\] and B). Thus, although Ras and Rap1 could both be activated by NT-3, they showed different spatial and temporal activation patterns.

![**Rap1, not Ras, is required for long-term morphological changes by NT-3.** (A) Activation of Ras and Rap1 in NT-3--stimulated *X. laevis* spinal neurons. Intensity-modulated display images of spinal neurons expressing Raichu--Ras or --Rap1 and stimulated by NT-3. Bar, 10 μm. Yellow arrows indicate spots with increased level of Ras or Rap1 activity (B) Quantitative analysis of Ras and Rap1 activities in neuronal soma. The relative changes in fluorescence intensity were monitored over time. *n* = 4. (C) Lack of effects of presynaptic expression of Dn-Ras or -Rap1 on NT-3--induced changes in SSC frequency. (D) Inhibition of NT-3--induced increase in synaptic site by presynaptic expression of Dn-Rap1, but not Dn-Ras. The number associated with each column represents the number of cells analyzed. Data are presented as the mean ± the SEM.](jcb1751029f08){#fig8}

Next, we asked whether the inhibition of Ras or Rap1 could block the long-term structural and functional change induced by NT-3. To test this, we expressed Dn-Ras or -Rap1 in *X. laevis* spinal neurons by embryo injection, and the nerve-muscle cocultures were treated with NT-3 for 2 d. Expression of Dn-Ras and -Rap1 did not affect basal synaptic transmission (compare the white bars in [Fig. 8 C](#fig8){ref-type="fig"}). Moreover, long-term treatment with NT-3 induced a similar increase in SSC frequency in control neurons and neurons expressing either Dn-Ras or -Rap1 ([Fig. 8 C](#fig8){ref-type="fig"} and Fig. S2 C). However, expression of Dn-Rap1, but not Dn-Ras, completely blocked the long-term effect of NT-3 on synaptic sites ([Fig. 8 D](#fig8){ref-type="fig"}). These data, together with the spatiotemporal pattern of Rap1 activation induced by NT-3, suggested that the Rap1--MAPK pathway was responsible for NT-3--induced long-term structural, but not functional, changes at the neuromuscular synapses.

Discussion
==========

It is well known that neuronal activity elicits long-term changes in the structure and function of synapses. Neurotrophins have recently emerged as a class of important regulators for synapse development and function. Neurotrophin-induced long-term synaptic changes resemble activity-dependent long-term synaptic plasticity in two fundamental ways: synaptic growth and dependence on protein synthesis ([@bib40]). A question of general interests is whether neuronal activity and neurotrophins use the same or different molecular mechanisms to modulate synapses. In this study, we show that NT-3 induced two parallel molecular pathways. One involves the CaMKIV--CREB pathway, which is responsible for enhancement of synaptic efficacy, but not synaptic growth. The other involves Rap1--MAPK, which leads to increase in the number of synaptic sites, but not in synaptic transmission. To our knowledge, no study so far has demonstrated that neuronal activity triggers two parallel, but distinct, signaling pathways for structural and functional plasticity in vertebrate synapses. Thus, although similar molecules are used to mediate synaptic modulation induced by either neuronal activity or neurotrophins, the specific mechanisms underlying the two types of synaptic modulation are not the same.

The results obtained from this study, together with our previous findings and those of other laboratories, support a model in which neurotrophins, through activation of Trk receptor tyrosine kinases, induce long-term structural and functional changes at synapses through two parallel signaling pathways ([Fig. 9](#fig9){ref-type="fig"}). The Ca^2+^--CaMKIV--CREB pathway ensures maturation of transmitter-release machinery for efficient functional transmission. The endocytosed Trk receptors and activation of Rap1--MAPK pathway promotes synaptic growth, leading to the development of properly matched pre- and postsynaptic structures. For proper development of neuromuscular synapse in vivo*,* both pathways have to be activated in concert. Having one ligand to trigger both pathways synchronously is an ideal way to coordinate the structural and functional development of synapses. Similar mechanisms may also apply to synapse regeneration after injury. Local secretion of neurotrophins may ensure simultaneous morphological and physiological recoveries of the injured synapses. Thus, concomitant activation of these two pathways via pharmacological means may help treatment of nerve injuries or other neurodegenerative diseases.

![A model for mechanisms underlying long-term modulation of structures and functions of synapses by NT-3.](jcb1751029f09){#fig9}

CaMKIV--CREB pathway mediates NT-3--induced physiological changes at synapses
-----------------------------------------------------------------------------

The transcription factor CREB has been extensively studied for its role in long-term, activity-dependent modulation of synapses in both vertebrates and invertebrates. In invertebrates, CREB has been shown to play a critical role in the long-term facilitation (LTF) at the *Aplysia* sensory-motor synapses ([@bib4]). Moreover, [@bib14] have shown that CREB is involved in functional, but not structural, plasticity at the *D. melanogaster* neuromuscular synapses. At mammalian hippocampal synapses, early studies suggest that CREB is also essential for late-phase LTP (L-LTP; [@bib11]). In contrast, several recent studies indicated that CREB plays a more important role in cell survival than synaptic plasticity in the hippocampus ([@bib54]; [@bib6]; [@bib56]). However, expression of constitutively active CREB facilitates L-LTP, as well as long-term memory ([@bib7], [@bib8]). Therefore, the specific role of CREB in activity-dependent synaptic modulation in vertebrate is an interesting subject that requires further investigation. We have now shown that CREB mediates the long-term changes in synaptic efficacy induced by NT-3. This is the first demonstration of the role of CREB in synaptic modulation by neurotrophins. Moreover, CREB is selectively involved in the physiological, but not morphological, changes of synapses induced by neurotrophins. These results suggest that activity-dependent and neurotrophin-induced synaptic modulation may use different molecular mechanisms, and provide new insights into a complex, but important, problem in the field.

In vitro studies have shown that CREB can be phosphorylated on Ser-133 by the following three signaling pathways: PKA, CaMKIV, and MAPK. However, specific pathways leading to CREB activation in neurons under physiologically relevant situations need to be worked out individually. Given that CREB is a key player in activity-dependent synaptic modulation, there has been considerable interest in determining the specific signaling events that activate CREB. Using cultured hippocampal neurons, some studies showed that neuronal activity rapidly induces a translocation of calmodulin from cytosol to nucleus and activation of CaMKIV, leading to CREB phosphorylation ([@bib10]; [@bib16]; [@bib23]). In contrast, [@bib27] argued that Ras-ERK-Rsk2 is more important than CaMKIV in activating CREB. Subsequent work by [@bib72] suggested that CaMKIV is responsible for the initial stage of fast CREB activation (2--10 min after stimulation), whereas MAPK is more effective in a later stage to promote a slow, but sustained, CREB phosphorylation. However, an activity-dependent rise in pCREB was greatly attenuated in both initial and late stages in CaMKIV-deficient mice ([@bib25]; [@bib58]). In transgenic mice overexpressing Dn-CaMKIV, activity-dependent activation of CREB was selectively blocked, whereas that of MAPK was normal ([@bib31]). These mice exhibit selective impairments in L-LTP, but not early-stage LTP, and in long-term memory, but not short-term memory. These results suggest that CaMKIV is a predominant pathway to CREB activation, and that the MAPK pathway can be subsidiary or dispensable.

What is the signaling event that activates CREB during neurotrophin-induced synaptic potentiation? Our previous studies demonstrated that upon NT-3 application, there is a rise in intracellular Ca^2+^, primarily through the release of Ca^2+^ from IP3 receptor stores in *X. laevis* spinal neurons ([@bib24]). We now showed that NT-3 induced the translocation of CaM into the nucleus, which is a prerequisite for CaMKIV activation. Furthermore, we found that CaMKIV is the only kinase that mediates NT-3--induced CREB phosphorylation, regardless of its temporal stages ([Fig. 1, C and D](#fig1){ref-type="fig"}). Most importantly, inhibition of CaMKIV, but not PKA or MAPK, blocked the NT-3--induced synaptic potentiation. These results unequivocally define the CaMKIV--CREB pathway that mediates the NT-3--induced synaptic potentiation.

Another interesting finding is that inhibition of CREB activity does not block the morphological changes in the nerve terminals induced by NT-3. This segregates the structural and functional alterations induced by the same neurotrophin. In *Aplysia,* injection of oligonucleotides containing multiple CRE-binding sites into the cell bodies of presynaptic sensory neurons represses both structural and functional changes underlying LTF ([@bib9]). In contrast, CREB function is only required in change of synaptic strength, but not synaptic growth, at the developing neuromuscular junction in *D. melanogaster* ([@bib14]). In the mammalian hippocampus, although the specific role of CREB in L-LTP remains debatable, it is generally agreed that CREB is important for long-term, activity-dependent modulation of synaptic efficacy ([@bib63]; [@bib30]; [@bib38]; [@bib70]; [@bib17]). There is some evidence that CREB is involved in long-term structural changes of hippocampus synapses, but in these cases CREB acts downstream of hormones or trophic factors, rather than mediating the effects of neuronal activity ([@bib49]; [@bib50]; [@bib34]).

Why, then, is CREB involved in structural plasticity in some systems, but not in others? One possibility is that the neuromuscular synapse is a unique system where CREB is not involved in structural plasticity. Alternatively, studies on *Aplysia* sensory motor synapses and hippocampal synapses deal with synaptic plasticity in the adult, whereas those using *X. laevis* nerve-muscle cocultures and *D. melanogaster* larvae NMJ reveal properties of developing synapses. A third possibility is that at the neuromuscular junction, CREB is activated strictly in presynaptic neurons, leading to transcription of genes important for synaptic transmission and plasticity. In the hippocampal neurons, CREB is activated largely in postsynaptic neurons. It is conceivable that postsynaptic CREB activation may result in production of proteins involved in synaptic growth. We favor a different interpretation; whether CREB is involved in morphological changes at synapses or not may represent a fundamental difference between activity-dependent and neurotrophin-induced synaptic modulation. In any case, separation of structural and functional plasticity offers a unique opportunity to study the molecular mechanisms underlying long-term synaptic modulation.

Rap1--MAPK pathway mediates NT-3--induced morphological changes at synapses
---------------------------------------------------------------------------

Numerous studies have revealed an undisputable role of MAPK in activity-dependent synaptic plasticity. In *Aplysia*, the activation of ApMAPK, the homologue of Mawkish associated with and necessary for the establishment of LTF ([@bib5]). Substantial evidence indicates that MAPK is involved in both the induction and maintenance of L-LTP in the mammalian hippocampus ([@bib19]; [@bib59]; [@bib33]). If activity-dependent and neurotrophin-induced synaptic modulations share similar molecular mechanisms, one would expect that MAPK be critically involved in synaptic potentiation induced by neurotrophins. Remarkably, MAPK is not required for the neurotrophin modulation of synaptic efficacy at the developing neuromuscular synapses. Instead, it plays a critical role in the formation of synaptic boutons induced by NT-3. Again, our data support two main points: (1) molecular mechanisms underlying activity-dependent and neurotrophin-induced synaptic modulation may be different; and (2) NT-3 triggers two parallel signaling pathways, which are separately responsible for structural and functional maturation of the synapses.

The separation of physiological and morphological effects of NT-3 on synapses is quite intriguing. There are several examples in which manipulations altered synaptic morphology, but not physiology, or vice versa. In one case, retinal astrocytes secrete the extracellular matrix proteins thrombospondins, which increases the number of structural synapses that are functionally silent ([@bib12]). Another example is that deletion of Munc18 in mice leads to a complete loss of functional synaptic transmission, but ultrastructurally these synapses are completely normal ([@bib67]). It is possible that morphological development of synapses is not necessary for simple spontaneous and evoked synaptic transmission, but may be needed for the full-bloom capacity, plasticity, or long-term stability of synapses. On the other hand, one may imagine that development of synaptic structures through Rap1--MAPK pathway may not be sufficient, and additional molecular and functional elements must be in place to achieve fully functional synapses.

An interesting finding was that Rap1, but not Ras, acts upstream of MAPK in mediating the increase in synaptic sites. How does Rap1 activation affect synaptic structure? One possibility is that only Rap1, but not Ras, mediates persistent MAPK activation, which may be required to trigger downstream signaling events necessary for structural plasticity. Parallel to this idea, previous studies indicate that NGF activates Ras through cell surface TrkA, leading to a transient activation of MAPK ([@bib75]). In contrast, NGF-induced endocytosis of TrkA activates Rap1, resulting in sustained MAPK activity ([@bib43]; [@bib75]; [@bib71]). Differences in the kinetics of MAPK activation may result in remarkably distinct cellular functions. In PC12 cells, transient activation of MAPK mediates proliferation, but sustained activation of MAPK induces differentiation ([@bib43]). We showed that application of NT-3 elicited a sustained activation of Rap1 localized largely in the cell body of spinal neurons, whereas Ras activation was transient and distributed throughout neuronal processes. Inhibition of Rap1, but not Ras, blocked the NT-3--induced MAPK activation and morphological changes of the nerve terminals. Rap1 may be involved in the signaling endosome to activate transcription. We have previously shown that endocytosis of NT-3 and its cognate receptor is required for NT-3--mediated long-term, but not short-term, synaptic modulation ([@bib28]). In PC12 cells, Rap1 and TrkA coprecipitate, and this signaling complex can affect MAPK activation ([@bib71]). Moreover, inhibition of receptor endocytosis attenuates activation of MAPK, but increases activation of other kinases ([@bib71]). Collectively, these results support the notion that the endocytosis of NT-3--TrkC complex results in a persistent activation of Rap1 and MAPK, which in turn trigger transcriptional activities that lead to the structural changes at the neuromuscular synapses.

An unsolved issue of Rap1--MAPK signaling in long-term synaptic modulation by neurotrophins is the identification of downstream targets of MAPK responsible for changing presynaptic morphology. One possibility is that the activation of MAPK affects cell adhesion molecules (CAMs), thereby modifying synaptic structures. The MAPK cascade has long been recognized as being required for growth factor--induced differentiation and outgrowth of nerve terminals ([@bib51]; [@bib52]). In *Aplysia*, LTF elicits translocation of activated ApMAPK into the neuronal nucleus and subsequent internalization of ApCAM, a homologue of fasciclin II (FasII) in *D. melanogaster* and nerve CAMs in mammals ([@bib46]). Mutation in MAPK or inhibition of MAPK phosphorylation in ApCAM blocks the internalization of ApCAM, thereby preventing synaptic growth ([@bib5]; [@bib44]). Similarly, at *D. melanogaster* NMJ, the modification of MAPK activity levels results in an altered number of synaptic boutons by affecting FasII localization at synaptic boutons ([@bib61],[@bib62]). Therefore, neurotrophic activation of MAPK may affect cell adhesion molecules or other downstream proteins to remodel synaptic morphology. Another possibility is that neurotrophins may trigger MAPK to activate transcription factors other than CREB. Adf1, a member of the Myb-related family of transcription factors known to be activated by MAPK, has been shown to promote the development of synaptic morphology in *D. melanogaster* NMJ; genetic manipulation that decrease (or increase) the amount of ADF1 gives rise to a decrease (or increase) in synaptic bouton numbers in *D. melanogaster* NMJ, without affecting synaptic strength ([@bib18]). However, synaptic proteins under ADF1 regulation or upstream of ADF1 have not yet been identified. Therefore, it will be interesting to resolve downstream targets for neurotrophic activation of MAPK that mediate changes in synaptic morphology.

Materials and methods
=====================

DNA constructs, embryo injection, and *X. laevis* nerve-muscle coculture
------------------------------------------------------------------------

dnCREB cDNA constructs (K- and A-CREB) were purchased from CLONTECH Laboratories, Inc. Dn-CaMKIV was a gift from M. Ehlers (Duke University Medical Center, Durham, NC). GFP-CaM expression vector was a gift from D. Chang (Hong Kong University of Science and Technology, Hong Kong, China). Dn-Ras and -Rap1a were gifts from A. Imamoto (University of Chicago, Chicago, IL). Raichu-Ras and -Rap1a were obtained from M. Matsuda (Osaka University, Osaka, Japan). cDNAs were digested and subcloned into the expression vector pcDNA3.1(+), which contains a T7 promoter for in vitro transcription of sense mRNAs. Capped mRNAs were generated by using the mMessage mMachine kit (Ambion). *X. laevis* egg laying was induced by injecting female *X. laevis* with human chronic gonadotropin (Sigma-Aldrich). Resulting eggs were fertilized artificially with sperms derived from male testis. mRNAs for NT-3, Dn forms of CREBs, Ras and Rap1a, or CaMKIV were mixed with 1 μg/μl GFP mRNA at a 1:1 ratio. Approximately 6--12 nl of the solution was injected into one blastomere at the 2- or 4-cell embryonic stage using the Picospitzer pressure ejector (Parker Hannifin). 1 d after injection, the neural tube and associated myotomal tissues were dissected and used to prepare nerve-muscle cultures. Neural tube and associated myotomal tissue of *X. laevis* embryos at stage 20 were dissociated in Ca^2+^-Mg^2+^--free medium (58.2 mM NaCl, 0.7 mM KCl, and 0.3 mM EDTA, pH 7.4) for 15--20 min. Cells were plated on clean glass coverslips and grown in the presence or absence of NT-3 (2 nM; a gift from Regeneron Pharmaceuticals, Tarrytown, NY) for 2 d at room temperature, as previously described ([@bib69]). The culture medium consisted (vol/vol) of 50% L-15 medium, 1% fetal calf serum, and 49% Ringer\'s solution (117.6 mM NaCl, 2 mM CaCl~2~, 2.5 mM KCl, and 10 mM Hepes, pH 7.6). Various inhibitors and NT-3 were added to the cultures 6 h after plating, when cells were completely settled.

Electrophysiology
-----------------

Synaptic currents were recorded from innervated muscle cells in 2- or 3-d-old cultures by the whole-cell recording method in culture medium at room temperature ([@bib69]). The internal pipette solution contained 150 mM KCl, 1 mM NaCl, 1 mM MgCl~2~, and 10 mM Hepes buffer, pH 7.2. The membrane potentials of the muscle cells recorded were generally in the range of --55 to --75 mV and were voltage clamped at --70 mV. All data were collected by a patch clamp amplifier (Axonpatch 200B; Axon Instruments), with a current signal filter set at 3 kHz. SSC frequency is defined as the number of SSC events per minute. The amplitudes of SSCs were analyzed using SCAN software (Dagan). To elicit ESCs, square current pulses (0.5--1 ms; 0.5--5 V) were applied to the soma of spinal neurons with a patch electrode filled with Ringer\'s solution at the neuronal soma under loose seal conditions ([@bib73]). Pipette and membrane capacitance and seal resistance were compensated. For acute effect, the data from a 10-min recording before application of NT-3 was taken as "control," and those from a 10-min recording after the increase has reached peak as "NT-3 treated." For long-term effect, a 10-min mean volume of SSC frequency/amplitude taken from any parts of the recording from a synapse gave rise to very similar numbers. For the convenience of comparison, we averaged data from control synapses without NT-3 treatment (control), and normalized data from all other conditions to the control. The numbers in the graph bars represent the number of synapses examined ([Figs. 2](#fig2){ref-type="fig"}, [3](#fig3){ref-type="fig"}, [5](#fig5){ref-type="fig"}, [6](#fig6){ref-type="fig"}, [8](#fig8){ref-type="fig"}, S2, and S3).

Quantification of synaptic sites and FM dye imaging
---------------------------------------------------

To visualize synaptic varicosity, we coinjected a small volume of a mixture, consisting of 2 μl of SYP-GFP plasmid DNA (1 μg/ml) and 2 μl of rhodamine-conjugated dextran dye (molecular weight, 10,000 D), by embryo injection. SYP-GFP construct was a gift from J. Sullivan (University of Washington, Seattle, WA). To label postsynaptic AChRs, 100 nM Cy5-labeled α-bungarotoxin (α-BTX) was applied to culture medium for 20 min. Cells were then rinsed extensively with Ringer\'s solution to remove unbound α-BTX. Confocal imaging was performed using an inverted LSM 510 META laser scanning microscope using 1.3 NA oil-immersion objectives (both Carl Zeiss MicroImaging, Inc.). For triple-color imaging, excitation lines of a 488-nm argon laser and two 543- and 640-nm helium lasers were used. Fluorescence was detected using a 488-/543-/633-nm dichroic beam splitter and a 530--560-nm bandpass filter for SYP-GFP, a 580--620-nm bandpass filter for rhodamine, and a 650-nm long-pass filter for Cy5. With the narrow band-pass filters, any crossover or bleed-through of fluorescence was eliminated. Postacquisition images were analyzed by IPLab software (Scanalytics). The criteria for synaptic puncta were that their fluorescence intensity must be \>100% above the background and their size must be \>0.5 μm in diameter. By using the region of interest (ROI) tool in the IPLab program, the number of synaptic sites, SYP-GFP puncta that juxtaposed with Cy5-α-BTX puncta within a myocyte, were measured. The calculated number of synaptic sites in a single myocyte per neuron were pooled and averaged. *t* tests were used for statistical analysis. The numbers in the bar graphs represent the number of cells used for morphological analysis ([Figs. 1](#fig1){ref-type="fig"}, [3 C](#fig3){ref-type="fig"}, [4](#fig4){ref-type="fig"}, [7 B](#fig7){ref-type="fig"}, and S1 B). For FM dye imaging, the fluorescent styryl membrane dye FM 4--64 (Invitrogen) was loaded into *X. laevis* spinal neurons by applying high K^+^ loading solution (60 mM KCl, 57.6 mM NaCl, 3.5 mM CaCl~2~, 10 mM Hepes, pH 7.6, and 2 μM FM 4--64) to cultures for 2 min. Cells were then rinsed extensively with Ringer\'s solution to remove membrane-bound FM dye. Fluorescent images of FM-dye were acquired by a cool charge-coupled device camera (MicroMax 1300; Roper Scientific) mounted on an inverted epifluorescence microscope (IX70; Olympus) and analyzed. Fluorescence images were taken with 500-ms exposure time with a ×40, 0.55 NA, objective.

Western blotting
----------------

*X. laevis* embryos at stage 20 were quickly homogenized in extraction buffer (100 mM NaCl, 50 mM Tris-HCl, pH 7.5, 1% NP-40, 2 mM PMSF, 1 μg/ml aprotinin, 1 μg/ml leupeptin, 1 μg/ml pepstatin A, and 2 μM Na~3~VO~4~) and subsequently sonicated. High-speed centrifugation produced an insoluble pellet that was discarded. Supernatants were transferred to a fresh tube containing 300 μl Freon (1,1,2-trichlorotrifluoroethane; Sigma-Aldrich), vortexed for 1 min, incubated on ice for 5 min, and centrifuged again to remove yolk protein. The protein concentrations of the supernatants were determined using the BioRad protein assay (BioRad Laboratories). The proteins were separated by SDS-polyacrylamide electrophoresis, and blotted onto Immobilon-P membrane (Millipore). The blots were probed with primary antibodies, anti-CaM (1:100), and anti-GFP (1:10,000; Cell Signaling Technology), followed by a secondary antibody conjugated with HRP. Signals were detected by a chemiluminescence kit (Pierce Chemical Co.).

Immunocytochemistry
-------------------

*X. laevis* nerve-muscle cultures were treated with or without pharmacological drugs for 30 min at room temperature before NT-3 application. The cultured were fixed 30 min after NT-3 application by using 4% paraformaldehyde (EM Science) for 30 min at room temperature, and washed three times with 0.1 M NaBH~4~ (sodium borohydrate) in PBS to reduce autofluorescence. Fixed cells were permeabilized with 0.1% Triton X-100 in PBS for 5 min. Fixed cells were blocked with 5% nonfat milk and incubated with primary antibodies against phospho-CREB 1:200 (Cell Signaling Technology) overnight at 4°C. Secondary antibody for immunofluorescence was Alexa Fluor 546 (Invitrogen). To visualize DAB staining, an ABC kit (Vector Laboratories) was used. The images of immunocytochemistry were captured with an Olympus IX70 microscope using a charge-coupled device camera, acquired with IPLab software and processed with Photoshop (Adobe).

FRET-based Raichu-Rap and -Ras imaging
--------------------------------------

Confocal imaging was performed using an inverted LSM 510 laser scanning microscope and 40×, 1.3 NA, or 63×, 1.3 NA, oil-immersion objectives (all from Carl Zeiss MicroImaging, Inc.). For imaging coexpression of YFP and GFP constructs, excitation lines of a blue diode laser of 405 nm for both CFP and YFP were used. Fluorescence was detected using a 458-/ 514-nm dichroic beam splitter and a 470--525-nm bandpass filter for CFP and a 530--590-nm bandpass filter for YFP. In this way, any cross-talk and bleed-through of fluorescence were eliminated. Time-lapse scanning was performed with LSM 510 imaging system software. Post acquisition image processing was performed with the LSM 5 Image Browser (Carl Zeiss MicroImaging, Inc.) and Photoshop 7.0 software (Adobe). *X. laevis* spinal neurons plated on a 35-mm diam coverslip were expressing pRaichu-derived plasmids by embryonic injection. A phase-contrast image and fluorescent images for ECFP and EYFP were recorded every 20 s. Starting from 5 min, cells were stimulated with 10 ng/ml NT-3. We demonstrated cell images in intensity-modulated display (IMD) mode by MetaMorph software (Molecular Devices), according to the manufacturer\'s instructions. In brief, background-subtracted images of EYFP and ECFP were first used for calculating of the EYFP/ECFP ratio of each pixel. After determination of the upper and lower thresholds, the ratio value of each pixel was associated with one of six hues from black (low) to white (high). The intensity of each pixel was determined by the brightness of ECFP. Thus, in IMD mode, the hue and its intensity at each pixel represent the FRET efficiency and the probe concentration, respectively. The FRET images were collected every 20 s.

Online supplemental material
----------------------------

Fig. S1 shows that NT-3 activates CREB. Fig. S2 shows the SSC amplitude data for K-CREB, Dn-CaMKIV, and Dn-Ras, Dn-Rap1 (A--C), and SSC frequency data for Rp-cAMP. Fig. S3 shows that inhibition of CaMKIV activation does not prevent an acute effect of NT-3 on synaptic transmission. Online supplemental material is available at <http://www.jcb.org/cgi/content/full/jcb.200603061/DC1>.
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